The Cannabis Investor is excited to announce MariMed Inc. (OTCQB: MRMD) as our new stock pick 🌿📈

Our research department took their time combing through filings and meeting with management in order to be certain MRMD was the right investment to show our followers. After considering Cannabis market conditions as well as MRMD’s fundamental and technical analysis we feel this is the perfect time to show you this new investment opportunity.

It’s no secret the Marijuana market has been red hot and we feel MRMD could be the next major mover in the space. Read the entire post to learn why. If you have any questions about MRMD please direct message us.

MariMed Inc. (OTCQB: MRMD) designs, develops and operates new state-licensed, state-of-the-art cultivation, production, and dispensing facilities throughout the US. The company has also vertically integrated a number of unique cannabis-infused consumer products through a network of franchisees within legalized states.

Per Cowen & Company 2017 report legal Cannabis will be a $50 billion U.S. industry and is in revolutionary transformation. MariMed’s diverse expertise and historical performance in the legal Cannabis industry is capitalizing on a significant share of this expanding market.

Why Invest in MRMD? 💵📈

✅ Highly profitable operating model
✅ Positioned to become the gold standard in the legal cannabis
✅ Rapid industry growth
✅ Proven record of success
✅ Innovative formulations
✅ Differentiated Product Brand
✅ Experienced management team
✅ Comprehensive service platform

Differentiated Branded Products: Kalm Fusion & Betty’s Eddies 🍬

➡️ Innovative all natural cannabis-infused products.
➡️ Precision dosed for consistency.
➡️ Available in THC and CBD formulation
➡️ Currently selling in RI, DE and IL
➡️ Rolling out in CA, CO, OR, NV and WA
➡️ Targeting 5,000+ dispensaries across 11 states

MRMD Technical Analysis & Chart 📈📊

As you can see from the chart below MRMD has recently went through a significant retracement after an impressive run this past summer. This is good news for you if are just now considering a potential entry.
MRMD has recently tested its long-term support of $0.25 5 times in the past month. We are happy to report that support successfully held up all 5 times. The stock also just made a new higher low adding further confirmation that the bottom very well could be in.
We have seen this same bottom formation recently in many other Cannabis stocks before making a reversal and resuming the uptrend. A quick look at the RSI also backs up the bottom formation as it recently made a higher low as well and is now trending up. The MRMD technicals are turning bullish. A major reversal in the stock price could be underway. All factors considered make this an attractive potential entry.

MRMD Chart:

Recent Press and Media 📰

MariMed Inc. Reports Record Third Quarter 2017 Financial Results
MariMed Inc. Begins National Expansion of Cannabis Infused Product Line In Nevada
MariMed Expanding Kalm Fusion™ Cannabis Products to Multiple States
Cannabis Science Pioneer Tikun Olam Expands Partnership with MariMed to Bring Branded Cannabis Products to More U.S. MMJ States
MRMD Featured in Microcap Review
Expert Tips On How To Make Money In The Cannabis Industry (According To Industry Leaders)

Due Diligence Links 📝

Corporate Website:

Follow MariMed on Social Media 🖥️🐦📸




This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Venture Capitalist and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Venture Capitalist’s controlling parent company has been compensated $9,500 per month for 12 months by MariMed Inc. (MRMD). The Wealthy Venture Capitalist’s controlling parent company has also been compensated 325,000 restricted shares by MariMed Inc. (MRMD). The Wealthy Venture Capitalist encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Venture Capitalist makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage. Readers must visit our website at in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.

Leave a Reply

Your email address will not be published. Required fields are marked *

pour la musculation tamoxifen buylivraison anonyme, prix favorable As a rule, the infection occurs during penetrative sexual intercourse buy metronidazole no prescription moist environment and can remain viable. cialis 20mg rezeptfreider Wirkstoff des Arzneimittels wird nicht verlassen, Zweifel an der Wirksamkeit der Pillen ein bewährtes Medikament zur Behandlung von BPH in einer Dosierung von 10 mg, die Möglichkeit gibt, ein neues Potential des Penis, um zu versuchen buy Retin AThis drug will no doubt help to solve the problem with acne in young people from 16 years, thanks to the active ingredient of this cream you will experience relief, people will stop laughing at you Diagnosticare la causa della disfunzione erettilecomprar cilaiscosì spesso il trattamento può comportare molteplici tecniche. Comprar cialis en línea

Wealthy Venture Capitalist